AstraZeneca PLC (LSE:AZN)
£ 122.46 -0.52 (-0.42%) Market Cap: 190.96 Bil Enterprise Value: 212.14 Bil PE Ratio: 38.14 PB Ratio: 6.48 GF Score: 85/100

Silence Therapeutics PLC Collaboration With AstraZeneca and R&D Update Call Transcript

Mar 25, 2020 / 01:00PM GMT
Release Date Price: £69.18 (-0.60%)
Operator

Good day, ladies and gentlemen, and welcome to the Silence Therapeutics Webcast and Conference Call.

(Operator Instructions) As a reminder, today's conference is being recorded. I would now like to turn the call over to Mr. Iain Ross, Executive Chairman. Please go ahead, sir.

Iain Gladstone Ross
Silence Therapeutics plc - Executive Chairman

Hi, good afternoon. We live an extraordinary time for the moment, and I hope everyone is well and safe. For us, at Silence, it's an extraordinary day because we think we've actually done an extraordinary deal and to manage to get this concluded over the last couple of weeks has been quite a challenge. What I'd like to do is basically introduce our speakers this afternoon. What I'm going to ask is for John Strafford, who's our Head of Business Development, to talk you through the collaboration that we've put together with AstraZeneca. And also for Rob Quinn, our Chief Financial Officer, to go through the numbers and give you some more detail. Then we'll move through to Giles Campion, who's going to give you an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot